Summary
Institut Curie is a cancer research foundation that operates cancer research institutes and hospitals and concentrates on the developing new treatments for cancer. The foundation carries out research in the areas of immunology, pharmachemistry, bioinformatics and systems biology, cell biology and developmental biology, genetics and carcinogenesis, cell and tissue imaging, and others. It provides care, research and training services for detecting, treating and monitoring cancer. Institut Curie offers services in anesthesia, medicine, pediatrics, surgery, tumor biology, intensive care, pain, medical imaging, and others. The foundation provides masters, PhD and postdoctoral fellowship programmes and other courses. Institut Curie is headquartered in Paris, France.
Institut Curie - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Institut Curie, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Institut Curie, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Institut Curie, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Institut Curie, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Institut Curie, Medical Devices Deals, 2011 to YTD 2017 9
Institut Curie, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Institut Curie, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Celyad Enters into Partnership with Institut Curie 11
Curie-Cancer Extends Co-Development Agreement with GamaMabs Pharma 12
Curie-Cancer Partners with Inventiva 13
Institut Curie Extends Research Agreement With Servier To Develop Breast Cancer Treatments 14
Curie-Cancer Enters into Co-Development Agreement with GamaMabs Pharma 15
Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 16
Curie-Cancer And GenoSplice Form Bioinformatics Partnership For Cancer Genomics 17
Curie-Cancer Enters Into Research Agreement With Harmonic Pharma 18
Licensing Agreements 19
Theravectys Enters into Licensing Agreement with Institut Curie 19
Abbott Molecular Enters into Licensing Agreement with Institut Curie 20
Meiogenix Enters Into Licensing Agreement With Curie-Cancer And Institut National de la Recherche Agronomique 21
Floralis Enters into Licensing Agreement with Ecrins Therapeutics 22
Institut Curie - Key Competitors 23
Institut Curie - Key Employees 24
Institut Curie - Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Government and Public Interest 26
May 13, 2016: Cervical Cancer And The HPV Virus: A New Tool For Understanding Tumour Diversity 26
May 13, 2016: HIV: Entry Keys Discovered in the Cell Nucleus 27
May 13, 2016: Breast Cancer: Blocking The First Steps in Tumour Invasion 28
May 13, 2016: Cervical Cancer: Initial Results from a European Study 29
Product News 30
Oct 17, 2016: Leukaemia: discovery of an interrupter that causes the death of tumorous cells 30
Jun 24, 2016: Uveal Melanoma: A Promising Avenue for Treating Metastatic Forms 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32
List of Tables
Institut Curie, Pharmaceuticals & Healthcare, Key Facts 2
Institut Curie, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Institut Curie, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Institut Curie, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Institut Curie, Deals By Therapy Area, 2011 to YTD 2017 8
Institut Curie, Medical Devices Deals, 2011 to YTD 2017 9
Institut Curie, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Celyad Enters into Partnership with Institut Curie 11
Curie-Cancer Extends Co-Development Agreement with GamaMabs Pharma 12
Curie-Cancer Partners with Inventiva 13
Institut Curie Extends Research Agreement With Servier To Develop Breast Cancer Treatments 14
Curie-Cancer Enters into Co-Development Agreement with GamaMabs Pharma 15
Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 16
Curie-Cancer And GenoSplice Form Bioinformatics Partnership For Cancer Genomics 17
Curie-Cancer Enters Into Research Agreement With Harmonic Pharma 18
Theravectys Enters into Licensing Agreement with Institut Curie 19
Abbott Molecular Enters into Licensing Agreement with Institut Curie 20
Meiogenix Enters Into Licensing Agreement With Curie-Cancer And Institut National de la Recherche Agronomique 21
Floralis Enters into Licensing Agreement with Ecrins Therapeutics 22
Institut Curie, Key Competitors 23
Institut Curie, Key Employees 24
List of Figures
Institut Curie, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Institut Curie, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Institut Curie, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Institut Curie, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Institut Curie, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Institut Curie, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Institut Curie, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Institut Curie, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Institut Curie, Medical Devices Deals, 2011 to YTD 2017 9
